OptimizeRx (OPRX) 46th Annual William Blair Growth Stock Conference summary

Corporate and financial overview

• Currently trading at $5.38 with a market cap just over $100 million and $20 million in cash; debt expense recently halved after refinancing.

• Leadership team includes experienced executives from pharma, finance, and legal backgrounds, driving operational discipline and growth.

• Last year saw 20%+ growth; this year impacted by client disruption but recovery expected in the back half and strong outlook for 2027.

• Reported nearly $20 million in quarterly revenue and over $3 million in adjusted EBITDA; last year’s adjusted EBITDA was almost $25 million on just under $110 million in revenue.

• Guidance for the upcoming year is slightly down due to macro factors and client disruption, but adjusted EBITDA is expected to remain strong at $21–$25 million.

Business model and technology

• Operates as a fully integrated point-of-care platform within EHRs, reaching 2 million healthcare providers and 240 million patients across 300+ EHRs.

• AI-driven Dynamic Audience Activation Platform (DAAP) leverages five years of longitudinal patient data to deliver targeted messaging to physicians and patients in real time.

• DAAP adoption is growing, now at 10% recurring revenue, with significant opportunity for further penetration and upselling within existing pharma clients.

• Platform supports over 400 active brands, with 45% coverage in the top 200 brands and a $2–$3 billion opportunity from current clients alone.

• Consistently delivers industry-leading ROI, with script lift and outcomes well above industry norms, verified through case studies and client campaigns.

Market opportunity and growth strategy

• Point-of-care digital pharma market estimated at $1.5–$2 billion within a $10 billion digital TAM; company is still early in market penetration.

• Recent partnerships with demand-side platforms (DSPs) like DeepIntent expected to double business size in 24 months and automate inventory acquisition.

• Expansion into DSPs and automated channels will accelerate growth and reduce reliance on direct sales to manufacturers.

• Significant push into the long tail of pharma and MedTech clients, driving diversification and high revenue per employee ($800,000+).

• Competitive moat established through early EHR integration and patented technology, making large-scale competition difficult.